

Final - October 16, 2018

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

1600 Clifton Road, NE, Tom Harkin Global Communications Center, Kent "Oz" Nelson Auditorium

Atlanta, Georgia 30329

October 24-25, 2018

| <u>AGENDA ITEM</u> | <u>PURPOSE</u> | <u>PRESIDER/PRESENTER(S)</u> |
|---|-----------------|--|
| Wednesday, October 24 | | |
| 8:00 Welcome & Introductions | | Dr. Amanda Cohn (ACIP Executive Secretary; CDC) |
| 8:30 Hepatitis A Vaccines | | |
| Introduction | | Dr. Kelly Moore (ACIP, WG Chair) |
| Background | Information | Dr. Noele Nelson (CDC/NCHHSTP) |
| Homelessness as a risk group: Evidence to Recommendation Framework and GRADE | & Discussion | Dr. Mona Doshani (CDC/NCHHSTP) |
| Public comment | | |
| Recommendation vote | <u>Vote</u> | Dr. Noele Nelson (CDC/NCHHSTP) |
| VFC vote | <u>VFC Vote</u> | Dr. Jeanne Santoli (CDC/NCIRD) |
| 10:15 | Break | |
| 10:30 Pneumococcal Vaccines | | |
| Introduction | | Dr. Grace Lee (ACIP, WG Chair) |
| PCV13 Impact on IPD and serotype distribution for the remaining disease burden | | Dr. Tamara Pilishvili (CDC/NCIRD) |
| Incidence of non-Invasive Pneumococcal Pneumonia before and after PCV13 recommendation for adults ≥65yo | Information | Mr. Ryan Gierke (CDC/NCIRD) |
| U.S. trends in pneumonia hospitalizations | & Discussion | Dr. Fernanda Lessa (CDC/NCIRD) |
| Economic analysis of PCV13 for adults ≥65 year old | | Dr. Charles Stoecker (Tulane University School of Public Health and Tropical Medicine) |
| Preliminary EtR and GRADE. Summary and timeline | | Dr. Almea Matanock (CDC/NCIRD) |
| 12:15 | Lunch | |
| 1:30 Adult Immunization Schedule | | |
| Introduction | Information & | Dr. Paul Hunter (ACIP, WG Chair) |
| Proposed 2019 adult immunization schedule | Discussion | Dr. David Kim (CDC/NCIRD) |
| 2:20 Child/Adolescent Immunization Schedule | | |
| Introduction | Information | Dr. Henry Bernstein (ACIP, WG Chair) |
| Proposed 2019 child and adolescent immunization schedule | & Discussion | Dr. Candice Robinson (CDC/NCIRD) |
| Public comment | | |
| Immunization schedules recommendations vote | <u>Vote</u> | Drs. David Kim and Candice Robinson (CDC/NCIRD) |
| 3:00 | Break | |
| 3:15 Japanese Encephalitis | | |
| Introduction | | Dr. Chip Walter (WG chair) |
| JE vaccine Evidence to Recommendations | Information & | Dr. Susan Hills (CDC/NCEZID) |
| JE-VC accelerated schedule recommendation for adults | Discussion | Dr. Susan Hills (CDC/NCEZID) |
| JE-VC pediatric booster and booster dose recommendations | | Dr. Susan Hills (CDC/NCEZID) |
| Conclusions and next steps | | Dr. Susan Hills (CDC/NCEZID) |
| 4:15 Anthrax | | |
| Introduction | | Dr. David Stephens (ACIP, WG Chair) |
| NuThrax® | Information | Dr. Paul- Andre de Lame, Mr. Jeff Shearer (Emergent BioSolutions) |
| Anthrax antitoxin for PEP | | Dr. William Bower (CDC/NCEZID) |
| 5:00 Vaccine Supply | | |
| 5:05 Public Comment | | |
| 5:20 Adjourn | | |

Final - October 16, 2018

Thursday, October 25

8:00 Agency Updates & Unfinished Business

CDC, CMS, DoD, DVA, FDA, HRSA, IHS, NIH, NVPO

Information

Dr. Nancy Messonnier (CDC/NCIRD); *Ex Officio* Members

8:30 Human Papillomavirus

Introduction

Vaccine safety update - no association with primary ovarian insufficiency

Background - Expanded age indication for 9vHPV GRADE

Impact and economic analyses

Recommendation options

Information & Discussion

Dr. Peter Szilagyi (ACIP, WG Chair)

Ms. Julianne Gee (CDC/NCEZID)

Dr. Lauri Markowitz (CDC/NCIRD)

Dr. Elissa Meites (CDC/NCIRD)

Dr. Harrell Chesson (CDC/NCHHSTP)

Dr. Lauri Markowitz (CDC/NCIRD)

10:15 *Break*

10:45 General Recommendations

Introduction

Background and posted changes since April 2017

Vaccine Administration – Vaccinators with conditions that are contraindications or precautions

Information & Discussion

Dr. Paul Hunter (ACIP, WG Chair)

Dr. Andrew Kroger (CDC/NCIRD)

Dr. Andrew Kroger (CDC/NCIRD)

11:15 Influenza

Introduction

Influenza vaccine effectiveness in preventing influenza-associated hospitalizations during pregnancy

Fluzone Quadrivalent 0.5-mL dose for children aged 6 through 35 Months

Information & Discussion

Dr. Chip Walter

Dr. Mark Thompson (CDC/NCIRD)

Dr. Monica Mercer (Sanofi Pasteur)

12:15 Rabies

Workgroup update

Information

Dr. Sharon Frey (ACIP, WG Chair)

12:20 Meningococcal

Workgroup Update

Information

Dr. David Stephens (ACIP, WG Chair)

12:25 Pertussis

Introduction to Work Group

Background to current ACIP recommendations (Td and Tdap) and policy considerations for Tdap revaccination

Adacel revaccination safety and immunogenicity

Boostrix revaccination safety and immunogenicity

Information

Dr. Henry Bernstein (ACIP, WG Chair)

Dr. Fiona Havers (CDC/NCIRD)

Dr. David Greenberg (Sanofi Pasteur)

Dr. Leonard Silverstein (GSK)

1:30 Public Comment

1:45 Adjourn

Acronyms

| | |
|---------|--|
| 9vHPV | 9-Valent Human Papillomavirus Vaccine |
| CDC | Centers for Disease Control & Prevention |
| CMS | Centers for Medicare and Medicaid Services |
| DoD | Department of Defense |
| DVA | Department of Veterans Affairs |
| FDA | Food and Drug Administration |
| GRADE | Grading of Recommendations Assessment, Development and Evaluation |
| HRSA | Health Resources and Services Administration |
| IHS | Indian Health Service |
| IPD | Invasive pneumococcal disease |
| JE-VC | Vero cell culture-derived Japanese encephalitis vaccine |
| NCHHSTP | National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID] |
| NCIRD | National Center for Immunization & Respiratory Diseases [of CDC/OID] |
| NCEZID | National Center for Emerging and Zoonotic Diseases [of CDC/OID] |
| NVPO | National Vaccine Program Office |
| PEP | Post-exposure prophylaxis |
| PCV13 | 13-valent pneumococcal conjugate vaccine |
| Td | Tetanus and diphtheria vaccine |
| Tdap | Tetanus, diphtheria, and pertussis vaccine |
| VFC | Vaccines for Children |
| WG | Work Group |